|
1
|
Mortada R and Williams T: Metabolic
syndrome: Polycystic ovary syndrome. FP Essent. 435:30–42.
2015.PubMed/NCBI
|
|
2
|
Hardiman P, Pillay OS and Atiomo W:
Polycystic ovary syndrome and endometrial carcinoma. Lancet.
361:1810–1812. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Akgül S, Düzçeker Y, Kanbur N and Derman
O: Do different diagnostic criteria impact polycystic ovary
syndrome diagnosis for adolescents? J Pediatr Adolesc Gynecol.
31:258–262. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Goodarzi MO, Dumesic DA, Chazenbalk G and
Azziz R: Polycystic ovary syndrome: Etiology, pathogenesis and
diagnosis. Nat Rev Endocrinol. 7:219–231. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Asunción M, Calvo RM, Millán JL, Sancho
J, Avila S and Escobar-Morreale HF: A prospective study of the
prevalence of the polycystic ovary syndrome in unselected Caucasian
women from Spain. J Clin Endocrinol Metab. 85:2434–2438. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Amiri M, Tehrani FR, Bidhendi-Yarandi R,
Behboudi-Gandevani S, Azizi F and Carmina E: Relationships between
biochemical markers of hyperandrogenism and metabolic parameters in
women with polycystic ovary syndrome: A systematic review and
meta-analysis. Horm Metab Res. 51:22–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fitzgerald S, DiVasta A and Gooding H: An
update on PCOS in adolescents. Curr Opin Pediatr. 30:459–465. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Szydlarska D, Machaj M and Jakimiuk A:
History of discovery of polycystic ovary syndrome. Adv Clin Exp
Med. 26:555–558. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rotterdam ESHRE/ASRM-Sponsored PCOS
Consensus Workshop Group, : Revised 2003 consensus on diagnostic
criteria and long-term health risks related to polycystic ovary
syndrome. Fertil Steril. 81:19–25. 2004. View Article : Google Scholar
|
|
10
|
Neven ACH, Laven J, Teede HJ and Boyle JA:
A summary on polycystic ovary syndrome: Diagnostic criteria,
prevalence, clinical manifestations, and management according to
the latest international guidelines. Semin Reprod Med. 36:5–12.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang R and Mol BWJ: The Rotterdam criteria
for polycystic ovary syndrome: Evidence-based criteria? Hum Reprod.
32:261–264. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu Z, Hao C, Song D, Zhang N, Bao H and
Qu Q: Androgen receptor coregulator CTBP1-AS is associated with
polycystic ovary syndrome in Chinese women: A preliminary study.
Reprod Sci. 22:829–837. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Patel S: Polycystic ovary syndrome (PCOS),
an inflammatory, systemic, lifestyle endocrinopathy. J Steroid
Biochem Mol Biol. 182:27–36. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sung YA, Oh JY, Chung H and Lee H:
Hyperandrogenemia is implicated in both the metabolic and
reproductive morbidities of polycystic ovary syndrome. Fertil
Steril. 101:840–845. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Norman RJ, Dewailly D, Legro RS and Hickey
TE: Polycystic ovary syndrome. Lancet. 370:685–697. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gelmann EP: Molecular biology of the
androgen receptor. J Clin Oncol. 20:3001–3015. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Meng D, Yang S, Wan X, Zhang Y, Huang W,
Zhao P, Li T, Wang L, Huang Y, Li T and Li Y: A transcriptional
target of androgen receptor, miR-421 regulates proliferation and
metabolism of prostate cancer cells. Int J Biochem Cell Biol.
73:30–40. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Takayama KI: Splicing factors have an
essential role in prostate cancer progression and androgen receptor
signaling. Biomolecules. 9:1312019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Baculescu N: The role of androgen receptor
activity mediated by the CAG repeat polymorphism in the
pathogenesis of PCOS. J Med Life. 6:18–25. 2013.PubMed/NCBI
|
|
20
|
Bevan CL, Hoare S, Claessens F, Heery DM
and Parker MG: The AF1 and AF2 domains of the androgen receptor
interact with distinct regions of SRC1. Mol Cell Biol.
19:8383–8392. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu J, Qiu Y, DeMayo FJ, Tsai SY, Tsai MJ
and O'Malley BW: Partial hormone resistance in mice with disruption
of the steroid receptor coactivator-1 (SRC-1) gene. Science.
279:1922–1925. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cheng S, Brzostek S, Lee SR, Hollenberg AN
and Balk SP: Inhibition of the dihydrotestosterone-activated
androgen receptor by nuclear receptor corepressor. Mol Endocrinol.
16:1492–1501. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Berrevoets CA, Umar A, Trapman J and
Brinkmann AO: Differential modulation of androgen receptor
transcriptional activity by the nuclear receptor co-repressor
(N-CoR). Biochem J. 379:731–738. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Takayama KI, Horie-Inoue K, Katayama S,
Suzuki T, Tsutsumi S, Ikeda K, Urano T, Fujimura T, Takagi K,
Takahashi S, et al: Androgen-responsive long noncoding RNA CTBP1-AS
promotes prostate cancer. EMBO J. 32:1665–1680. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Takayama K, Tsutsumi S, Katayama S,
Okayama T, Horie-Inoue K, Ikeda K, Urano T, Kawazu C, Hasegawa A,
Ikeo K, et al: Integration of cap analysis of gene expression and
chromatin immunoprecipitation analysis on array reveals genome-wide
androgen receptor signaling in prostate cancer cells. Oncogene.
30:619–630. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Czermin B, Melfi R, McCabe D, Seitz V,
Imhof A and Pirrotta V: Drosophila enhancer of Zeste/ESC complexes
have a histone H3 methyltransferase activity that marks chromosomal
Polycomb sites. Cell. 111:185–196. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Montgomery ND, Yee D, Chen A, Kalantry S,
Chamberlain SJ, Otte AP and Magnuson T: The murine polycomb group
protein Eed is required for global histone H3 lysine-27
methylation. Curr Biol. 15:942–947. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ji XY, Tan B and Zhu YZ: Salvia
miltiorrhiza and ischemic diseases. Acta Pharmacol Sin.
21:1089–1094. 2000.PubMed/NCBI
|
|
30
|
Wang X, Morris-Natschke SL and Lee KH: New
developments in the chemistry and biology of the bioactive
constituents of Tanshen. Med Res Rev. 27:133–148. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Havelock JC, Rainey WE and Carr BR:
Ovarian granulosa cell lines. Mol Cell Endocrinol. 228:67–78. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Morita Y and Tilly JL: Oocyte apoptosis:
Like sand through an hourglass. Dev Biol. 213:1–17. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Buccione R, Schroeder AC and Eppig JJ:
Interactions between somatic cells and germ cells throughout
mammalian oogenesis. Biol Reprod. 43:543–547. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Erickson GF, Magoffin DA, Garzo VG, Cheung
AP and Chang RJ: Granulosa cells of polycystic ovaries: Are they
normal or abnormal? Hum Reprod. 7:293–299. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jakimiuk AJ, Weitsman SR, Navab A and
Magoffin DA: Luteinizing hormone receptor, steroidogenesis acute
regulatory protein, and steroidogenic enzyme messenger ribonucleic
acids are overexpressed in thecal and granulosa cells from
polycystic ovaries. J Clin Endocrinol Metab. 86:1318–1323. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu Q, Wang G, Li Q, Jiang W, Kim JS, Wang
R, Zhu S, Wang X, Yan L, Yi Y, et al: Polycomb group proteins EZH2
and EED directly regulate androgen receptor in advanced prostate
cancer. Int J Cancer. 145:415–426. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yu J, Yu J, Mani RS, Cao Q, Brenner CJ,
Cao X, Wang W, Wu L, Li J, Hu M, et al: An integrated network of
androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in
prostate cancer progression. Cancer Cell. 17:443–454. 2010.
View Article : Google Scholar : PubMed/NCBI
|
